IP Library Granted Patent US 9,991,012
Granted Patent B2
US 9,991,012 · App. 13/878,252 · Granted Jun 5, 2018

Extraction process

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,991,012
App. No.
13/878,252
Granted
Jun 5, 2018
Kind
B2
Abstract

A process for extracting Cs-137 from i) an acidic solution obtained by dissolving an irradiated solid target comprising uranium, ii) an acidic solution comprising uranium which has previously been irradiated in a nuclear reactor, or iii) an acidic solution comprising uranium which has been used as reactor fuel in a homogeneous reactor, the acidic solution i), ii) or iii) having been treated to harvest Mo-99, wherein the process comprises contacting the treated acidic solution with an adsorbent comprising ammonium molybdophosphate (AMP). In an embodiment, the AMP is combined with an organic or inorganic polymeric support, for example AMP synthesized within hollow aluminosilicate microspheres (AMP-C).

Claims (14)

1. A process for extracting Cs-137 from i) an acidic solution obtained by dissolving an irradiated solid target comprising uranium, ii) an acidic solution comprising uranium which has previously been irradiated in a nuclear reactor, or iii) an acidic solution comprising uranium which has been used as reactor fuel in a homogeneous reactor, the process comprising

(a) harvesting Mo-99 from the solution i), ii) or iii) prior to extracting Cs-137,

(b) contacting the acidic solution from step (a) with an adsorbent comprising ammonium molybdophosphate (AMP) to extract Cs-137, and

(c) when the solution is solution ii) or solution iii), returning the depleted Cs-137 solution from step (b) to the nuclear reactor or the homogenous reactor;

wherein harvesting Mo-99 from the acidic solution prior to step (b) prevents the Mo component present in the AMP from leaching into and contaminating the Mo-99.

2. A process according to claim 1 , wherein the AMP is combined with an organic or inorganic polymeric support.

3. A process according to claim 2 , wherein the AMP combined with an inorganic polymeric support is AMP that is synthesised within hollow aluminosilicate microspheres (AMP-C).

4. A process according to claim 1 , wherein Mo-99 is harvested from solution ii) or iii) in step (a), and the process further comprises a step of removing Mo, leached from the AMP, from the Cs-137-depleted solution prior to its return to be irradiated in the nuclear reactor, or prior to its return to the homogeneous reactor.

5. A process according to claim 4 , wherein the step of removing Mo, leached from the AMP, from the Cs-137-depleted solution comprises contacting said Cs-137-depleted solution with a zirconium-containing sorbent.

6. The process of claim 5 , wherein the zirconium-containing sorbent is a zirconium/titania-based sorbent.

7. An apparatus for carrying out the process of claim 1 , the apparatus comprising a vessel containing an adsorbent for the extraction of Mo-99, a source of the uranium containing acidic solution of claim 1 arranged in fluid communication with the vessel containing an adsorbent for the extraction of Mo-99, and a vessel containing an adsorbent comprising ammonium molybdophosphate (AMP) and arranged in downstream fluid communication with the vessel containing the adsorbent for extraction of Mo-99.

8. An apparatus according to claim 7 , further comprising a nuclear reactor for the production of Mo-99, wherein the nuclear reactor has a valve at its outlet, the vessel containing an adsorbent for the extraction of Mo-99 is arranged, and the vessel containing an adsorbent comprising AMP is arranged in downstream fluid communication with the valve and in downstream fluid communication with the vessel containing an adsorbent for the extraction of Mo-99.

9. An apparatus according to claim 7 , further comprising a homogeneous reactor, which uses a solution comprising uranium as reactor fuel for the production of Mo-99, wherein the homogeneous reactor has a valve at its outlet, the vessel containing an adsorbent for the extraction of Mo-99 is arranged, and the vessel containing an adsorbent comprising AMP is arranged in downstream fluid communication with the valve and in downstream fluid communication with the vessel containing an adsorbent for the extraction of Mo-99.

10. An apparatus according to claim 7 , the apparatus further comprising a vessel containing an adsorbent for removing Mo, leached from the AMP, in downstream fluid communication with the vessel containing an adsorbent comprising AMP.

Assignments (6)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTEREST Recorded Jan 31, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: MALLINCKRODT NUCLEAR MEDICINE LLC
Reel/Frame 041131/0213 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2016
From: MALLINCKRODT LLC
To: MALLINCKRODT NUCLEAR MEDICINE LLC
Reel/Frame 039149/0234 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2013
From: BARBOSA, LUIS A.M.M.
To: MALLINCKRODT INC.
Reel/Frame 030222/0161 →
CHANGE OF LEGAL ENTITY Recorded Apr 16, 2013
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 030222/0758 →